Abbott's second-quarter Diagnostics segment posted 42.3% reported sales growth, but comparable growth came in at just 2.9%. The gap stems from the March 23 acquisition of Exact Sciences, which added its Cancer Diagnostics business to Abbott's portfolio. U.S. Diagnostics sales surged 104.8% on a reported basis, yet comparable growth was 4.0%. The Cancer Diagnostics unit, built around Cologuard colorectal screening tests, grew 13.3% on a comparable basis, driven by what the company describes as a growing base of new and repeat users

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

July 16, 2026 08:19 ET (12:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.